This would represent a double-edged sword for prostate cancer survival and progression, as the inhibition observed could favor resistance to apoptosis by siRNA TMPRSS2-ERG treatment or decrease dedifferentiation and therefore enhance cancer cell death. This evidence concerns the gene TMPRSS2 and Familial prostate cancer.